Thursday, 26 February 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 26 February 2026
News

Hyped drug fails to reach Aust

Posted 26 February 2026 AM

BioMarin has voluntarily pulled Roctavian from all markets before the one-shot gene therapy for haemophilia A could even reach Australia.

In 2023, Roctavian made Clarivate’s 15-strong Drugs to Watch list, which names candidates set to either deliver annual sales of more than US$1 billion in the next five years or transform paradigms to meet unmet patient needs – the same year it was accepted for TGA review under orphan status.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (11)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.